Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose risk in transgender men and women

Award Number: SC1DA052120
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2020
PERIOD OF PERFORMANCE END DATE: 03/21/2025

Group Awards By:

View Award Description

GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose risk in transgender men and women - ABSTRACT Gamma-hydroxybutyrate (GHB), is a popular drug of abuse utilized at raves and in drug-facilitate sexual assault due to its’ euphoric, aphrodisiac, and sedative effects. The annual number of GHB-associated deaths has continued to increase since the 1990s in the United States, the United Kingdom, Western Europe and Australia. In the last decade the use of GHB has been increasing in the LBGTQ community due to the prevalence of a phenomenon referred to as chemsex. Of the drugs used for chemsex, GHB is the most likely to cause acute overdose. Proton- and sodium-dependent monocarboxylate transporters (MCTs/SMCTs) are involved in the transport of GHB across biologically important barriers and tissues, and their expression governs GHB renal clearance and brain distribution. Preliminary data demonstrates that GHB toxicokinetics (plasma concentrations and renal clearance) are altered in the presence and absence of female sex hormones. Further, we have demonstrated that male and female sex hormones regulate monocarboxylate transporters in the kidney, and differences in GHB renal clearance over the estrous cycle, and between males and females are consistent with the changes in renal monocarboxylate transporter expression. Despite the potential for sex hormones to regulate GHB renal clearance and tissue distribution, there is a paucity of information in the literature regarding the influence of sex and cross-sex hormone treatment on GHB toxicokinetics and toxicity. The focus of this application is on investigating GHB toxicokinetics in response to sex and cross-sex hormone therapy and identifying the sex hormone-dependent mechanisms regulating expression of renal and blood brain barrier (BBB) monocarboxylate transporters. Our overall hypothesis is that variability in GHB toxicokinetics and overdose risk result from sex hormone-dependent regulation of monocarboxylate transporters that govern GHB clearance and distribution. We have proposed two specific aims to evaluate this hypothesis utilizing in vivo models of sex and cross-sex hormone replacement, molecular biological and toxicokinetic techniques. The first specific aim investigates GHB toxicokinetics and toxicity in response to sex and cross-sex hormone treatment. Our hypotheses for this aim are that [1] GHB renal clearance and systemic exposure (AUC) will be altered in response to individual male and female sex hormones; [2] males, and animals exposed to testosterone will have an increased risk of acute overdose due to decreased renal clearance. In our second aim, we will investigate the sex hormone-dependent regulation of renal and BBB MCTs and SMCTs. Our hypotheses are that sex and cross- sex hormone treatment will differently regulate monocarboxylate transporter expression, and this regulation is sex hormone receptor dependent. This proposal represents a novel extension of our previous work, and will further our mechanistic understanding of sex hormone-dependent regulation of drug clearance, and the resultant toxicokinetic consequences, and will help to identify populations with a greater risk of GHB overdose.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$62,068 )
2025	2023	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	001	4	7/2/2025	TERMINATION	-$62,068
2025	2023	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	000	4	3/21/2025	TERMINATION	$0
														Subtotal = -$62,068

Issue Date FY: 2023 ( Subtotal = $290,624 )
2023	2023	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	000	4	3/15/2023	NON-COMPETING CONTINUATION	$290,624
														Subtotal = $290,624

Issue Date FY: 2022 ( Subtotal = $289,440 )
2022	2022	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	000	3	3/17/2022	NON-COMPETING CONTINUATION	$289,440
														Subtotal = $289,440

Issue Date FY: 2021 ( Subtotal = $288,291 )
2021	2021	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	000	2	3/16/2021	NON-COMPETING CONTINUATION	$288,291
														Subtotal = $288,291

Issue Date FY: 2020 ( Subtotal = $287,148 )
2020	2020	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	001	1	3/26/2020	NEW	$0
2020	2020	UNIVERSITY OF PACIFIC	3601 PACIFIC AVE	STOCKTON	CA	95211	SAN JOAQUIN	USA	Drug Use and Addiction Research Programs	000	1	3/23/2020	NEW	$287,148
														Subtotal = $287,148

Grand Total All Awards = $1,093,435

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose risk in transgender men and women

Award Number: SC1DA052120

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2020

PERIOD OF PERFORMANCE END DATE: 03/21/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer